GlassScriptPhysician profile
Nicole Bright
NPI 1578722856
$22,577.90
in general payments reported to CMS, 2019-2025
37 companies · $6,553 in 2025
The $6,553 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $1,479 · 2021: $1,642 · 2022: $2,124 · 2023: $4,190 · 2024: $5,017 · 2025: $6,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,753 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,110 · Consulting Fee: $2,340 · Education: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,752.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,109.50 |
| Consulting Fee | $2,340.00 |
| Education | $557.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,076.24 | 2019-2025 | |
| Janssen Biotech, INC. | $3,779.35 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $2,564.66 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $1,532.34 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,434.44 | 2019-2025 | |
| Ucb, INC. | $1,336.50 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,148.16 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $993.16 | 2019-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $782.77 | 2019-2025 | Siliq, Targretin, Cabtreo |
| Incyte Corporation | $778.77 | 2021-2025 | Opzelura |
| Amgen INC. | $732.42 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $542.24 | 2022-2024 | Sotyktu |
| Prugen, INC. Pharmaceuticals | $425.75 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $401.18 | 2021-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $393.67 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $242.35 | 2019-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $158.94 | 2022-2024 | |
| Dermavant Sciences, INC. | $145.78 | 2023-2024 | Vtama |
| Genentech USA, INC. | $133.23 | 2019-2025 | Xolair, Erivedge |
| Arcutis Biotherapeutics, INC. | $122.24 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.03 | 2022-2025 | Spevigo |
| Biofrontera INC. | $94.48 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Celgene Corporation | $86.41 | 2019 | |
| Encore Dermatology INC. | $80.53 | 2019-2020 | |
| Mission Pharmacal Company | $59.14 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $55.28 | 2025 | Acthar |
| Organon LLC | $54.88 | 2024-2025 | |
| Strata Skin Sciences, INC. | $54.49 | 2022-2024 | Xtrac |
| Dermira, INC. | $50.38 | 2020-2021 | |
| Epi Health, LLC | $47.91 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $46.25 | 2024 | Idacio |
| Vyne Pharmaceuticals INC. | $27.93 | 2020 | |
| Boston Scientific Corporation | $18.07 | 2025 | Wavewriter Alpha Prime 16 |
| Krystal Biotech INC | $18.02 | 2024 | Vyjuvek |
| Taro Pharmaceuticals USA, INC. | $17.74 | 2019 | |
| Journey Medical Corporation | $13.80 | 2023 | |
| Merck Sharp & Dohme LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.